Orforglipron efficacy and safety for weight maintenance after GLP-1/GIP agonist treatment evaluated
Background
Effective treatments like injectable GLP-1/GIP receptor agonists (e.g., tirzepatide, semaglutide) have revolutionized obesity management, leading to significant body weight reduction. However, maintaining this weight loss, particularly after transitioning from injectable therapies, remains a critical challenge. Patients often experience weight regain upon discontinuation. Orforglipron, an oral GLP-1 receptor agonist, is being investigated as a convenient option to sustain weight reduction and address this unmet need for long-term weight management.
Study Design
This double-blind, randomized phase 3b ATTAIN-MAINTAIN trial evaluates orforglipron for weight maintenance. Participants previously completed the SURMOUNT-5 trial, receiving injectable tirzepatide or semaglutide. They are randomized to receive either placebo or oral orforglipron capsule formulation at a maximum tolerated dose (12, 24, or 36 mg) for 52 weeks. A standardized dose escalation schedule precedes the maintenance phase. The primary objective is to assess the efficacy and safety of orforglipron in maintaining body weight reduction.
Why It Matters
This trial addresses a critical need for effective and convenient long-term weight maintenance strategies following initial significant weight loss with injectable GLP-1/GIP receptor agonists. If successful, oral orforglipron could offer a practical alternative to continued injectable therapy, improving adherence and patient quality of life. This could allow clinicians to transition patients to an oral regimen for sustained weight management, potentially reducing the burden of self-injection. The study's focus on participants already achieving weight reduction with established injectables provides a real-world context for its potential utility in clinical practice, shaping future obesity treatment protocols.
orforglipron
obesity
weight loss
weight management
glp-1 agonist
clinical trial